Compare Quest Diagnostics Inc (DGX) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Quest Diagnostics Inc trades at $205.18 (market cap $22.80B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.72. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| DGX | QDTY | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $216.02 | $46.71 |
52-Week Low | $166.42 | $36.57 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
QDTY trades at $40.43, down 1.84% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Recent weekly dividend announcements from YieldMax ETFs highlight the fund's distribution strategy, though key financial ratios are currently unavailable for fundamental assessment.
The outlook remains cautious with technical indicators pointing to continued weakness. Investment opportunity hinges on the ETF's ability to maintain consistent distributions, while risks include market volatility and the absence of clear valuation metrics. Investors should await updated financial disclosures for fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
